IADR Abstract Archives
Impact of Resolvin D2 on Periodontal Inflammation and Adverse Pregnancy Outcomes
Objectives: The aim of this study was to determine the preventive treatment impact of resolvin D2 (RvD2) on periodontal disease induced pregnancy complications.
Methods: Eighteen female C57BL/6J mice were divided into 3 experimental groups: Control (No disease or treatment); Periodontitis (F. nucleatum 25586-induced periodontitis) and Treatment (F. nucleatum 25586-induced periodontitis+RvD2 treatment). Mice were topically infected with oral gavage of 1×109 live bacteria/100μl in PBS on a daily basis over a 6-week period. RvD2 (0.2mg/per animal in 20 microliter PBS) was topically applied prior to each oral bacterial gavage. In all groups, mice were then mated. Pregnant mice were sacrificed and tissues harvested at embryonic day (E) 16.5. Fetus weights and numbers were evaluated. Placentae were analyzed for inflammation and necrosis. Cytokine responses were evaluated by Luminex.
Results: The Periodontitis-group had significantly more bone loss and osteoclastic activity than the control group (p<0.05). RvD2 prevented the F. nucleatum-induced periodontal bone loss and osteoclastic activity in alveolar bone. Fetus weights were decreased in the periodontitis group (6.60±1.90) compared to the control group (8.79±1.53, p<0.05). RvD2 treatment restored the fetus weight and number to the control group levels. When the placenta sections were examined, inflammatory infiltration was observed in samples from the Periodontitis-group. Placenta levels of IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, and TNFα were elevated in the periodontitis group, but only IL-13 levels were statistically significant (p<0.05). RvD2 treatment resulted in a significant reduction in placental inflammation. There was a positive correlation between bone loss and IL-13 level (r=0.655, p=0.015).
Conclusions: The data suggest that periodontal disease leads to adverse pregnancy outcomes; preventing periodontitis prevents adverse pregnancy outcomes, in spite of the exposure to F. nucleatum suggesting that the inflammatory process induced by periodontal disease is associated with the systemic inflammation and pregnancy complications.
Methods: Eighteen female C57BL/6J mice were divided into 3 experimental groups: Control (No disease or treatment); Periodontitis (F. nucleatum 25586-induced periodontitis) and Treatment (F. nucleatum 25586-induced periodontitis+RvD2 treatment). Mice were topically infected with oral gavage of 1×109 live bacteria/100μl in PBS on a daily basis over a 6-week period. RvD2 (0.2mg/per animal in 20 microliter PBS) was topically applied prior to each oral bacterial gavage. In all groups, mice were then mated. Pregnant mice were sacrificed and tissues harvested at embryonic day (E) 16.5. Fetus weights and numbers were evaluated. Placentae were analyzed for inflammation and necrosis. Cytokine responses were evaluated by Luminex.
Results: The Periodontitis-group had significantly more bone loss and osteoclastic activity than the control group (p<0.05). RvD2 prevented the F. nucleatum-induced periodontal bone loss and osteoclastic activity in alveolar bone. Fetus weights were decreased in the periodontitis group (6.60±1.90) compared to the control group (8.79±1.53, p<0.05). RvD2 treatment restored the fetus weight and number to the control group levels. When the placenta sections were examined, inflammatory infiltration was observed in samples from the Periodontitis-group. Placenta levels of IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, and TNFα were elevated in the periodontitis group, but only IL-13 levels were statistically significant (p<0.05). RvD2 treatment resulted in a significant reduction in placental inflammation. There was a positive correlation between bone loss and IL-13 level (r=0.655, p=0.015).
Conclusions: The data suggest that periodontal disease leads to adverse pregnancy outcomes; preventing periodontitis prevents adverse pregnancy outcomes, in spite of the exposure to F. nucleatum suggesting that the inflammatory process induced by periodontal disease is associated with the systemic inflammation and pregnancy complications.